Navigation Links
No evidence to support stem cell therapy for pediatric optic nerve hypoplasia
Date:10/21/2013

pate in the study; Children's Hospital was to find case matched controls from their clinic. However, only two case-controlled pairs were evaluated because Beike Biotech was only able to recruit two patients. Treatments consisted of six infusions over a 16-day period of umbilical cord-derived mesenchymal stem cells and daily infusions of growth factors. Visual acuity, optic nerve size, and sensitivity to light were to be evaluated one month before stem cell therapy and three and nine months after treatment.

No therapeutic effect was found in the two case-control pairs that were enrolled. "The results of this study show that children greater than 7 years of age with ONH may have spontaneous improvement in vision from one examination to the next. This improvement occurs equally in children regardless of whether or not they received treatment. Other aspects of the eye examination included pupil responses to light and optic nerve size; these did not change following treatment. The results of this research do not support the use of stem cells in the treatment of ONH at this time," says lead author Cassandra Fink, MPH, program administrator at The Vision Center, Children's Hospital Los Angeles.

Confounding the trial was that subjects received additional alternative therapies (acupuncture, functional electrical stimulation, and exercise) while receiving stem cell treatments, which was contrary to the trial protocol. The investigators could not determine the effect of these additional therapies.

"This study underscores the importance of scientifically testing these procedures to validate them and also to ensure their safety. Parents of afflicted children should be aware that the science behind the use of stem cell technology is unclear. This study takes a step toward testing this technology and finds no beneficial effect," says William V. Good, MD, Senior Associate Editor, Journal of AAPOS and Clinical Professor of Ophthalmology and Senior
'/>"/>

Contact: Eileen Leahy
e.leahy@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New evidence that cancer cells change while moving throughout body
2. Exploring the Latest Evidence of Dairys Contribution to Nutrition at IUNS Satellite Symposium
3. New evidence for warm-blooded dinosaurs
4. Evidence suggests Antarctic crabs could be native
5. ACRG and BGI report new evidence for the genetic bases of liver cancer
6. First international collaboration to showcase latest body of evidence of dairy health benefits
7. First evidence that the genome can adapt to temperature changes
8. Evidence of host adaptation of avian-origin influenza A virus
9. New evidence on how fluoride fights tooth decay
10. AACR news: Studies show increasing evidence that androgen drives breast cancer
11. New evidence dinosaurs were strong swimmers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2015)... 14, 2015 Research and Markets ( ... "Fingerprint Sensors Market in Smart Mobile Devices " ... that 2014 was a watershed year for fingerprint sensors ... ,Apple Pay,. Apple gave fingerprint sensors a raison d,etre ... Fingerprint sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... and Prevention (CDC) today released new infection control ... Carbapenemase (KPC)-Producing Organisms, one of the ... shown that infections with these highly resistant bacteria ... In Guidance for Control of Infections with ...
... in German . The gene Myc is ... division. It causes the production of a protein which, as ... % of all human genes. When this gene mutates to ... Thereby the gene plays a decisive role in the development ...
... 18, 2009) Epidemiologists and computer scientists at the ... low-cost, green technology for automatically tracking the use of ... they exit patient rooms. This novel method of ... control in hospitals, was released today at the annual ...
Cached Biology News:Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms 2Pilot study shows effectiveness of new, low-cost method for monitoring hand hygiene compliance 2
(Date:5/26/2015)... NORTH CHICAGO, Ill. , May 26, 2015 ... biopharmaceutical company, announced today that it has completed ... and commercial presence in oncology. Pharmacyclics is a ... (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ... "The companies, shared expertise, combined with AbbVie,s broad ...
(Date:5/25/2015)... 2015  PureTech, a science-driven healthcare company seeking to ... ways, announced today that Dame Marjorie Scardino , ... Pearson, has been appointed to PureTech,s Board of Directors ... current Board member Joi Ito , MIT Media ... Ben Shapiro , PureTech,s outgoing Chairman and co-founder, former ...
(Date:5/22/2015)... DUBLIN , May 22, 2015  Actavis plc ... of the U.S. Court of Appeals for the Second ... 2014 preliminary injunction requiring the Company to continue distribution ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   ... uphold this ruling, we intend to continue our strong ...
(Date:5/22/2015)... DALLAS , May 22, 2015 Baylor ... and the Translational Genomics Research Institute (TGen) in ... that will focus on accelerating early detection and treatments for ... science of both institutions will lead to new clinical trials ... therapies – bridging the gap from bench to bedside across ...
Breaking Biology Technology:AbbVie Completes Acquisition of Pharmacyclics 2AbbVie Completes Acquisition of Pharmacyclics 3AbbVie Completes Acquisition of Pharmacyclics 4AbbVie Completes Acquisition of Pharmacyclics 5AbbVie Completes Acquisition of Pharmacyclics 6PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4
... on InterMune Phase 3 CAPACITY Program - ... patient retention rate in CAPACITY -, BRISBANE, Calif., Oct. ... on October 16, 2008, the Japanese,Ministry of Health, Labor and ... & Co. Ltd. to market pirfenidone,for the treatment of patients ...
... million to create a leading center for medical excellence; ... ... Fueled by a grant from the John S.,and James L. Knight ... the BioInnovation Institute in,Akron -- a unique collaboration that will expand ...
... ISTO Technologies, Inc., a privately,held orthobiologics company, ... injectable cell-based therapy for spinal disc,repair. The data ... Annual,Meeting of the North American Spine Society. Studies ... (UCSF) Department of Orthopedics,were designed to investigate potential ...
Cached Biology Technology:InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 2InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 3InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 4BioInnovation Institute in Akron Launched 2BioInnovation Institute in Akron Launched 3BioInnovation Institute in Akron Launched 4Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society 2
...
Mouse polyclonal antibody to QDPR - quinoid dihydropteridine reductase...
... The F10 tubing kit provides high-pressure ... DuoFlow system and other chromatography systems. ... Teflon, Tefzel, and orange PEEK tubing ... DuoFlow basic chromatography system running at ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
Biology Products: